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clearance (milliliters per minute) was calculated as dose 
• o~ • 103/A, where dose is expressed in milligrams, A is 
the intercept of the clearance curve on the concentra- 
tion axis (expressed in milligrams per liter), and a (per 
minute) = log2/TV2, where T1/2 is the clearance half- 
time (expressed in minutes). This calculation assumes 
that the hepatic extraction efficiency of ICG is essen- 
tially 100%. 4 
Mean cardiac output was just above baseline levels 
during CPB in all four groups of patients, and it 
increased by a further 6% to 25% after CPB (Table I). 
During normothermic CPB, mean liver blood flow did 
not change significantly in either the pulsatile group 
(14% mean decrease) or the nonpulsatile group (6% 
mean decrease); immediately after CPB, liver blood 
flow was significantly higher than baseline only in the 
patients receiving nonpulsatile perfusion (Table II). 
During hypothermic CPB, mean liver blood flow de- 
creased significantly compared with baseline in the 
pulsatile group (30% mean decrease) but not in the 
nonpulsatile group (13% mean decrease). 
We conclude that hepatic blood flow is well main- 
tained by both pulsatile and nonpulsatile flow during 
normothermic CPB at 2.4 L • min -1 • m -2. However, a 
decrease in liver blood flow during hypothermic perfu- 
sion is associated more with pulsatile than with nonpul- 
satile flow. These data support he previously published 
reports from clinical 2and animal 3 investigations, which 
noted preservation of liver blood flow during hypother- 
mic, nonpulsatile flow, together with loss of benefit 
owing to pulsatility at 2.4 compared with 1.2 L • min -1 
• m -2. They are also consistent with our recent clinical 
report of reduced gastric mucosal perfusion during 
hypothermic CPB. 5 The present findings thus support 
the view that an optimum CPB protocol for preserving 
the hepatic circulation requires a high perfusion rate 
with pulsatile or nonpulsatile flow at 37 ° C; if hypother- 
mia is used, a nonpulsatile protocol appears to be 
preferable to a pulsatile one. 
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METHEMOGLOBINEMIA COMPLICATING TOPICAL ANESTHESIA DURING BRONCHOSCOPIC 
PROCEDURES 
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Methemoglobinemia is potential complication of top- 
ical anesthesia during bronchoscopic procedures. If un- 
recognized, it can lead to death. The presentations and 
management of two patients in whom methemoglobin- 
emia developed after topical anesthesia with benzocaine 
during treatment with a flexible bronchoscope are pre- 
sented, followed by a brief review of the literature. 
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Clinical summaries 
PATIENT 1. A 67-year-old man underwent resection of a 
posterior mediastinal mass. On postoperative day 2 a 
chest roentgenogram showed complete opacification of 
the left lung field and a leftward shift of the mediastinal 
structures, consistent with a collapse of the left lung. A 
fiberoptic bronchoscope was inserted at the bedside with 
the aid of topical anesthesia. The nasopharynx was lubri- 
cated with viscous lidocaine and the oropharynx was 
sprayed twice with a 20% benzocaine solution (Hurricain e 
Spray). Bronchoscopic examination revealed significant 
mucus plugging of the left main-stem bronchus. Twenty 
minutes into the procedure the patient was noticed to be 
cyanotic. The oxygen saturation by pulse oximetry (Spo2) 
had dropped gradually from 94% at the beginning of the 
procedure to 60% to 65%. The patient became disori- 
ented and was promptly intubated. The initial arterial 
blood gas value immediately after intubation with the 
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patient receiving an inspired oxygen fraction of 1.0 re- 
vealed an oxygen tension of 271 mm Hg with a calculated 
oxygen saturation of 100%, despite the deeply cyanotic 
appearance of the blood sample. The methemoglobin 
level was analyzed by co-oximetry and determined to be 
35.4% with a measured oxygen saturation of 67.7%. 
Methylene blue dye (2 mg/kg) was administered intrave- 
nously as a 1% solution over 10 minutes. Within 20 
minutes after administration of the dye, the Spo 2 had 
returned to normal. The patient was extubated without 
difficulty the next day after an uneventful second broncho- 
scopic examination for which intratracheal 4% lidocaine 
was used as the anesthetic. 
PATIENT 2. Two weeks after patient 1 was treated, a 
66-year-old man with a history of coronary artery disease 
underwent a pulmonary resection (right upper lobecto- 
my), decortication, and pleural stripping for a 3 cm 
large-cell carcinoma with associated necrotizing pneumo- 
nia. On postoperative day 2 the patient was noted to have 
significant atelectasis of the right middle lobe. A fiberoptic 
bronchoscope was inserted at the bedside with the aid of 
topical anesthesia. The nasopharynx was lubricated with 
viscous lidocaine and the oropharynx was sprayed twice 
with a 20% benzocaine solution (Hurricaine Spray). The 
procedure, which lasted only 5 minutes, revealed minimal 
secretions and no significant mucus plugs. Ten minutes 
after the termination of the procedure, the patient's Spo2 
began to steadily decline to 60%. The patient's mental 
status did not change significantly, and he had no symp- 
toms of respiratory distress. The patient was given oxygen 
by means of a face mask and an arterial blood gas sample 
was drawn. The arterial oxygen tension from this deeply 
cyanotic sample was 347 mm Hg. A methemoglobin level 
could not be obtained because the in-hospital co-oximeter 
was not functioning. The patient was empirically given an 
intravenous dose of methylene blue dye, 2 mg/kg, and 
within 30 minutes the Spo 2 had normalized. 
Discussion. The flexible bronchoscope is commonly 
used for both diagnostic and therapeutic purposes by the 
busy thoracic surgeon. The introduction of the flexible 
fiberoptic bronchoscope by Ikeda in 1967 presented the 
thoracic surgeon with a valuable new diagnostic instru- 
ment. The instrument can be easily passed through the 
nose or mouth of an awake patient after the brief appli- 
cation of a topical anesthetic. Methemoglobinemia arising 
from topical anesthesia with benzocaine is a potential 
complication that, if unrecognized, can lead to death. 
Knowledge of and immediate attention to this complica- 
tion are critical in managing these patients. Although 
reports have surfaced describing this reaction during 
endotracheal intubation during anesthesia and in patients 
undergoing endoscopic examination of the upper part of 
the intestine, its occurrence during use of a flexible 
bronchoscope has not been widely reported in the tho- 
racic surgical iterature. 
Methemoglobin is formed when the heme iron of 
unoxygenated hemoglobin is oxidized to the ferric (Fe 3+) 
state. This is to be characterized from the physiologic 
equilibrium of oxygenated hemoglobin that exists between 
the ferric and ferrous states in relation to the capture and 
release of oxygen. Methemoglobin is not capable of 
carrying oxygen or carbon dioxide. In the erythrocyte, an 
equilibrium normally exists between hemoglobin and met- 
hemoglobin. In normal circumstances, only 1% of hemo- 
globin within the erythrocyte exists in the met form. The 
term methemoglobinemia refers to levels of methemoglo- 
bin greater than 1%. Normal evels of methemoglobin are 
maintained by two mechanisms: (1) the presence of 
reductive metabolic pathways that regulate the amount of 
oxidant substances which can oxidize the heme iron to the 
ferric state and (2) directly reducing the ferric iron state of 
methemoglobin to the ferrous state. The more important 
regulation is by conversion of methemoglobin to hemo- 
globin. This reduction of methemoglobin is carried out by 
the enzymes NADH methemoglobin reductase and 
NADPH methemoglobin reductase, with the former ac- 
counting for approximately 95% of reducing activity in 
vivo. Although enzymatic reduction of methemoglobin by
NADPH methemoglobin reductase accounts for only 5% 
of the total reducing activity, this reaction is greatly 
accelerated by the presence of methylene blue, which acts 
as a cofactor. 
Acquired hemoglobinemia occurs when the rate of 
formation of methemoglobin exceeds the rate of reduc- 
tion as a result of exposure to certain substances: amyl 
nitrite, aniline dyes, benzocaine, bismuth subnitrate, dap- 
sone, lidocaine, nitroglycerin, p-aminosalicylic acid, phe- 
nytoin, prilocaine, primaquine, pyridine, silver nitrate, and 
sulfonamides. Nitrites and aniline derivatives are the 
chemicals most commonly associated with methemoglo- 
binemia. The toxic effects of benzocaine appear to arise 
from the oxidizing capabilities of a metabolite that is most 
likely an N-hydroxy derivative. Animal and human data 
suggest that the formation of clinically significant methe- 
moglobinemia after exposure to benzocaine is limited to a 
small subgroup of patients. Differences in benzocaine 
metabolism may explain the variability in benzocaine- 
associated methemoglobinemia. I Lidocaine, which is also 
commonly used during bronchoscopic studies, has been 
demonstrated to cause methemoglobinemia. As demon- 
strated by the first patient, lidocaine can be used in 
patients ensitive to benzocaine although reports of met- 
hemoglobinemia occurring after lidocaine anesthesia in 
these patients exist. 2 Data within the existing literature are 
not sufficient o comment on the relative propensity of 
benzocaine versus lidocaine in inducing methemoglobin- 
emia. 
The clinical effects of methemoglobinemia derive from 
the blood's decreased oxygen-carrying capacity. Symp- 
toms include anxiety, headaches, fatigue, coma, and death 
and usually occur when the methemoglobin level exceeds 
30%. 3 When levels exceed 50% tissue oxygenation be- 
comes truly inadequate, resulting in dyspnea, acidosis, 
bradycardia, paralysis, coma, and convulsions. Death usu- 
ally occurs with levels above 70%. 3 Cyanosis is usually 
evident when the methemoglobin level is 10% to 15%, 
although in anemic individuals it can appear with levels of 
2.5%. The diagnosis of methemoglobinemia after topical 
anesthesia with benzocaine during bronchoscopic studies 
is suggested by the appearance of chocolate-colored cya- 
nosis and an oxygen-unresponsive drop in Spo2 as mea- 
sured by pulse oximetry. Reports in the literature have 
suggested that the Spo a with increasing levels of methe- 
moglobin plateaus at 85%. 4 We observed Spo 2 levels far 
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below this. Thus levels below 85% should not exclude the 
diagnosis of methemoglobinemia. The arterial blood sam- 
ple despite this low Spo 2 will reveal a normal or even 
elevated oxygen tension in the patient being provided 
oxygen. Qualitative measurement of methemoglobin lev- 
els are obtained with co-oximetry. 
The treatment of methemoglobinemia begins with gen- 
eral supportive care, including oxygen and control of the 
airway if necessary. Methylene blue given in a dose of 1 to 
2 mg/kg intravenously over 10 minutes is the treatment of 
choice. Methylene blue is reduced to leukomethylene blue 
by accepting electrons from NADPH in the presence of 
NADPH methemoglobin reductase. Leukomethylene 
blue then acts as an electron donor and nonenzymatically 
reduces methemoglobin to hemoglobin. 3 In higher doses, 
methylene blue can produce side effects including chest 
pain, dyspnea, tremors, and exacerbation of methemoglo- 
binemia by directly oxidizing hemoglobin to methemoglo- 
bin. Methemoglobin levels after administration of meth- 
ylene blue return to normal evels within 20 minutes to 1 
hour. If cyanosis persists beyond 1 hour, a second dose 
may be~ given. In severe or refractory cases, exchange 
transfusion may be used. Patients unresponsive to meth- 
ylene blue treatment may have a congenital deficiency in 
either glucose-6-phosphate d hydrogenase or NADPH 
methemoglobin reductase. 
In summary, benzocaine-induced methemoglobinemia 
should be considered in patients undergoing broncho- 
scopic study when cyanosis develops that is unresponsive 
to oxygen and associated with normal to high oxygen 
tensions. Diagnostic onfirmation by means of co-oxime- 
try if available should be performed. Intravenous methyl- 
ene blue is the treatment of choice in patients who have 
symptomatic levels or who are at high risk for cardiovas- 
cular events. Its use is contraindicated in patients with 
known glucose-6-phosphate d hydrogenase deficiency. 
Exchange transfusion should be considered in symptom- 
atic patients with near lethal levels. 
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PULMONARY THROMBOENDARTERECTOMY FOR THE TREATMENT OF PULMONARY 
EMBOLISM CAUSED BY RENAL CELL CARCINOMA 
Patrick Paw, MD, and Stuart W. Jamieson MB, FRCS, San Diego, Calif. 
Chronic pulmonary embolism with pulmonary hyper- 
tension is optimally treated by bilateral pulmonary throm- 
boendarterectomy with the use of cardiopulmonary b - 
pass and profound hypothermic circulatory arrest. 1With 
very few exceptions, chronic pulmonary embolism is a 
bilateral disease. However, we recently performed a uni- 
lateral pulmonary thromboendarterectomy with explora- 
tion of the contralateral side for a patient with a chronic 
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pulmonary embolus after a right nephrectomy for renal 
cell carcinoma. 
Clinical summary. The patient is a previously healthy 
40-year-old man who was referred for the evaluation and 
treatment of pulmonary hypertension. Three months ear- 
lier he had had chest pain and severe dyspnea on exertion. 
A ventilation/perfusion scan revealed the absence of 
perfusion to the entire left lung, with a few areas of 
subsegmental defects in the right lower lobe. He was 
initially treated with intravenous treptokinase, but this 
was discontinued because of a toxic reaction. After sys- 
temic anticoagulation, a computed tomographic scan of 
the abdomen and pelvis revealed a large renal tumor 
impinging on the inferior vena cava. A cardiac echocar- 
diogram demonstrated normal eft ventricular wall func- 
tion with no evidence of a right atrial or ventricular mass, 
a lower extremity duplex scan showed no deep venous 
thrombosis, magnetic resonance imaging of the head 
showed no abnormalities, and results of a bone scan were 
negative. 
A right nephrectomy was performed. Pathologic exam- 
ination showed a renal cell carcinoma with invasion into 
